By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, three Insight Molecular Diagnostics Inc. the people running the company added shares on the open market, about $5.7 million in total, and none of them sold.
Biggest single buyer: Bradsher Neal C, 10% Owner, with roughly $3 million.
On the institutional side, 40 funds reported holding IMDX at the end of Q2 2026, and funds were split between buying and selling. No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling IMDX stock?
In the last 12 months Insight Molecular Diagnostics Inc. insiders made open-market purchases worth about $5.7 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in IMDX?
The most recent open-market insider trade in IMDX was filed on 2026-04-27.
How many institutions own IMDX?
40 investment managers reported holding IMDX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded IMDX?
No congressional trades in IMDX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).